| __timestamp | Amphastar Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 9335772 |
| Thursday, January 1, 2015 | 174172000 | 999000 |
| Friday, January 1, 2016 | 150976000 | 978000 |
| Sunday, January 1, 2017 | 149380000 | 952000 |
| Monday, January 1, 2018 | 187681000 | 956000 |
| Tuesday, January 1, 2019 | 190434000 | 8122999 |
| Wednesday, January 1, 2020 | 206506000 | 8712000 |
| Friday, January 1, 2021 | 238029000 | 13980000 |
| Saturday, January 1, 2022 | 250127000 | 21135000 |
| Sunday, January 1, 2023 | 293274000 | 10755000 |
Unleashing the power of data
In the dynamic world of biopharmaceuticals, understanding cost structures is crucial. Amphastar Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. present a fascinating contrast in their cost of revenue trends from 2014 to 2023. Amphastar's cost of revenue has surged by approximately 84%, peaking in 2023, reflecting its expanding operations and market reach. In contrast, Iovance's costs have shown a more modest increase, with a notable spike in 2022, suggesting strategic investments in research and development. This divergence highlights the varied strategies within the industry, where Amphastar focuses on scaling production, while Iovance invests in innovation. These trends underscore the importance of strategic financial management in navigating the competitive biopharma landscape.
Cost of Revenue Trends: Novartis AG vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amgen Inc. and Amphastar Pharmaceuticals, Inc.
Sanofi vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Iovance Biotherapeutics, Inc.
Jazz Pharmaceuticals plc vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Cytokinetics, Incorporated vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Iovance Biotherapeutics, Inc.
Supernus Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Geron Corporation vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Iovance Biotherapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.